Docetaxel and 5-Fluorouracil: Promising Novel Regimen for Advanced Gastric Cancer
the Cancer Therapy Advisor take:
Researchers sought to establish a more complete understanding of a biweekly dose-dense regimen of docetaxel and 5-fluorouracil as first-line treatment for patients with advanced gastric cancer and the effect is has on matters such as efficacy, safety, and quality of life.
The study included 39 patients with a median age of 55 (range 28-80). The primary endpoint of the study was response rate, and secondary endpoints included progression-free survival, overall survival, quality of life, and toxicity.
Patients were given docetaxel 60 mg/m2 and 5-fluorouracil 400 mg/m2 bolus followed by 2,400 mg/m2 46-hour infusion every 2 weeks. All patients adopted prophylactic use of G-CSF. Researchers found that the response rate in patients was 51.3% and median overall survival and progression-free survival were 14.0 and 6.7 months, respectively.
Adverse events were reported at all grade levels, the most common being anemia (87.2%), fatigue (74.4%), neutropenia (66.7%), nail change (48.7%), and liver dysfunction (38.5%). Grade 3/4 toxicities were noted as anemia (28.2%), liver dysfunction (7.7%), and fatigue (7.7%). The researchers also conducted an analysis focused on quality of life and noted improvements in seven scales and drops in 3 scales.
The researchers concluded that a biweekly dose-dense regiment of docetaxel and 5-fluorouracil as first-line treatment for patients with advanced gastric cancer has promising indications as a tolerable and safe treatment option that improves response rates for patients.
Docetaxel and 5-fluorouracil as first-line treatment for patients with advanced gastric cancer.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Complete Resection of Metastatic Soft Tissue Sarcoma Associated With Improved Disease-specific Survival
- The Challenges of Immunotherapy Re-challenge in Metastatic Melanoma
- FDA Approves Fulvestrant/Abemaciclib Combination for Breast Cancer
- Beta-blockers May Prevent Stress-induced Lung Cancer Treatment Resistance
- Exercise May Mitigate Doxorubicin-related Cardiotoxicity
- FDA Expands Sunitinib Indication To Include Adjuvant Therapy for Renal Cell Carcinoma
- Ultrasonography May Detect Thyroid Cancer Growth Arrest, Negating Need for Treatment
- Does Education Level Predict PSA Screening and Prostate Cancer Survival?
- Unrelated HSCT, UCBT May Yield Similar Survival Outcomes in Acute Leukemia
- Minimal Residual Disease and Patient Genotype May Inform Relapse Risk Algorithms in ALL